| This is the talk page for discussing improvements to the Itramin tosilate article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Itramin tosilate.
|
Page title edit
@Kamdenek: I think the title of this article should be itramin tosilate. Per Wikipedia:WikiProject_Pharmacology/Style_guide#Articles_to_use_INN, articles about pharmaceutical drugs should be titled using the International Nonproprietary Name (INN). Although "tosylate" is the more common spelling in chemical nomenclature, "tosilate" is the spelling used for pharmaceutical drugs. Since the article is specifically about a pharmaceutical, the guidelines for that type of article should take precedence. To confirm the INN, see for example the FDA website https://precision.fda.gov/uniisearch/srs/unii/W9H0R50KY0 where the INN is specified. Reba16 (talk) 02:04, 15 September 2022 (UTC)
I do not understand. I opened the link above ( https://precision.fda.gov/uniisearch/srs/unii/W9H0R50KY0 ) and read: Preferred Substance Name: ITRAMIN TOSYLATE. Kamdenek (talk) 14:05, 15 September 2022 (UTC)
OK, now I noticed the "INN" in brackets. If you still think the title should be "itramin tosilate", feel free to move the page. Kamdenek (talk) 14:14, 15 September 2022 (UTC)